Generic Name and Formulations:
Ciclesonide 37mcg/actuation; metered-dose nasal aerosol; contains HFA.
Treatment of symptoms associated with seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) in patients ≥12yrs of age.
One actuation in each nostril once daily (37mcg/actuation); max 74mcg/day.
Conduct nasal examination before starting treatment. Discontinue if nasal erosion, ulceration, or perforation occurs. Active or quiescent respiratory tract tuberculosis. Infections (eg, ocular herpes simplex). If exposed to measles or chickenpox, consider immunoglobulin prophylactic therapy. If adrenal suppression exists following systemic corticosteroid therapy, replacement with topical steroids may exacerbate symptoms of adrenal insufficiency. Monitor for hypercorticism and HPA axis suppression (if occur discontinue gradually), and for candida infection and other nasal cavity changes. Monitor for growth suppression in children. Monitor for vision changes or if history of increased intraocular pressure, glaucoma or cataracts. Avoid spraying in eyes or directly onto the nasal septum. Pregnancy (Cat. C). Nursing mothers.
May be potentiated by ketoconazole.
Nasal discomfort, headache, epistaxis; ulcerations, nasal septal perforation, candida infection, impaired wound healing.
Nasal aerosol—6.1g (60 actuations)